Synjardy (EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)
Synjardy (EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Synjardy; Generic name: EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE; Drug class: Sodium-Glucose Cotransporter 2 Inhibitor [EPC].
| Brand name | Synjardy |
|---|---|
| Generic name | EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE |
| Drug class | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] |
| Manufacturer | Boehringer Ingelheim Pharmaceuticals, Inc. |
| Used for | 1 INDICATIONS AND USAGE SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adult |
| Dosage | 2 DOSAGE AND ADMINISTRATION Assess renal function before initiating and as clinically indicated. Assess volume status and correct volume depletion before initiating. ( 2.1 ) Individualize the starting dosage based on the patient's current regimen and renal function. ( 2.2 , 2.3 , 2.4 ) The maximum recommended dosage is 25 mg/day of empagliflozin and 2,000 mg/day of metformin HCl. ( 2.2 , 2.3 ) Initiation of SYNJARDY or SYNJARDY XR is not recommended in patients with an eGFR less than 45 mL/min/1 |
| Warnings | WARNING: LACTIC ACIDOSIS Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metformin-associated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metformin-associated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of |
| Active ingredient(s) | EMPAGLIFLOZIN |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fdd0255-0055-65f3-b2c0-db8fbb87beae |